Close Menu
    Facebook X (Twitter) Instagram
    Facebook Instagram Threads
    Global BiodefenseGlobal Biodefense
    Subscribe
    • Featured News
    • Funding
    • Directory
    • Jobs
    • Events
    Global BiodefenseGlobal Biodefense
    Industry News

    Ology Bioservices Awarded DoD Contract for Countermeasures Against Bioweapons

    By Global Biodefense StaffApril 15, 2019
    Yersinia pestis concept illustration
    Yersinia pestis concept illustration. Credit: Shutterstock
    Share
    Facebook LinkedIn Reddit Email

    The Department of Defense (DOD), through its Platforms for Rapid Integrated Solutions for Medical Countermeasures (PRISM) office, has awarded Ology Bioservices two contracts valued at $135.4 million.

    The first contract award is for the “Development and Utilization of a Monoclonal Antibody Platform Prototype for Development of Monoclonal Antibodies as Medical Countermeasures Against Threats of Interest.”

    This award, valued at $130.3 million over 10-years, is part of PRISM’s Advanced Development and Manufacturing of Antibody Technologies (ADAMANT) platform concept. ADAMANT explores how monoclonal antibodies can be used as next-generation medical countermeasures against chemical and biological threats.

    The target for this program is plague, a disease caused by infection with the bacterium Yersinia pestis. Plague has been responsible for several major, deadly pandemics throughout recorded history. As the plague is considered a potential biological weapon, the efforts of this program are focused on producing high quality monoclonal antibodies that will protect warfighters who may become exposed to this deadly agent.

    “To date, no one has successfully used monoclonal antibodies against Y. pestis as a treatment for plague in humans,” said Dr. Robert V. House, Senior Vice President, Government Contracts at Ology Bioservices. “This multiyear program, which will encompass solutions for discovery/design, manufacturing, testing, quality, regulatory strategy and program management, gives Ology Bioservices the unique opportunity to make meaningful strides in this arena. We have assembled a world-class team to assist us in this effort including the Duke Human Vaccine Institute, Just Biotherapeutics, Inc., Mapp Biopharmaceutical, Inc., the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID), Cato Research, Certara and Battelle.”

    PRISM also awarded Ology Bioservices a $5.1 million, 30-month contract entitled, “Developing, Establishing and Exercising Plasmid DNA Manufacturing Capabilities at the DOD Advanced Development and Manufacturing Facility.”

    Under this program, Ology Bioservices will develop and deliver a prototype manufacturing platform for the CGMP production of nucleic acids, primarily plasmid DNA for use as both Drug Substance and high-quality intermediate. Plasmid DNA is important, primarily for its use in DNA vaccines and gene therapy. The aim of the project is to more rapidly and efficiently deliver biodefense medical countermeasures to warfighters, with reduced developmental risk.

    This contract also includes optional components that would facilitate the development of capabilities for manufacturing RNA, another area of potential value to the U.S. government and commercial clients for various uses, including RNA vaccines.

    Ology Bioservices is a privately-held, full-service Contract Development Manufacturing Organization (CDMO) serving both government and commercial clients, specializing in biologic drug substance manufacturing, from early stage through commercial product. The company has 183,000 square feet of manufacturing, process development and QA/QC space in its state-of-the-art, Department of Defense Advanced Development and Manufacturing Facility in Florida. The company’s infrastructure provides unique services to its clients, including full regulatory support from preclinical through licensure, clinical trial operational support and bioanalytical testing, as well as cGMP manufacturing up to Biosafety Level 3 (BSL3). Ology Bioservices has 20 years of experience developing and manufacturing drugs and biologics for the U.S. Government, with over $500M in government contracts awarded over that time.

    Awards Battelle Editor Pick Select Agents Therapeutic Antibodies USAMRIID Y. pestis
    Share. Facebook LinkedIn Reddit Email
    Previous ArticleBARDA Extends Strategic Partnership with JLABS
    Next Article Burden of Measles on Public Health, Infectious Disease Physician Shortage, Ebola IHR Emergency Committee Meeting

    Related Stories

    Inflammatix Completes Development for Acute Infection and Sepsis Test System

    November 15, 2023

    Virginia Tech Lab Selected for National Partnership to Fight Emerging Diseases

    November 14, 2023

    NanoViricides’ Phase 1 Broad-Spectrum Antiviral Highly Effective for Mpox and Smallpox

    November 14, 2023

    COVID Moonshot Consortium Announces Crowd-Sourced Small Molecule Discovery

    November 11, 2023
    News Scan

    Biodefense Headlines – 30 November 2023

    News Scan November 30, 2023

    News highlights on health security threats and countermeasures curated by Global Biodefense This week’s selections include the largest ever outbreak of mpox in the DRC; launch of National Wastewater Surveillance Program dashboard; low uptake of COVID-19 boosters and flu vaccines;…

    Upcoming Events

    Mar 12
    Hybrid Hybrid Event
    March 12, 2024 - March 17, 2024

    2024 Fungal Genetics Conference

    Mar 21
    March 21, 2024 - March 23, 2024

    ASPPH 2024 Annual Meeting

    View Calendar

    Subscribe to Global Biodefense

    Get the latest news on pathogens and preparedness

    News on pathogens and preparedness for public health emergencies

    © 2023 Stemar Media Group LLC
    • About
    • Contact
    • Privacy
    • Subscribe

    Type above and press Enter to search. Press Esc to cancel.